|Status : Published||Published On : Feb, 2022||Report Code : VRHC1257||Industry : Healthcare||Available Format :||Page : 200|
The global CRISPR (clustered regularly interspaced short palindromic repeats) gene editing market is anticipated to grow from USD 1.12 billion in 2021 to USD 16.75 billion by 2027, registering a CAGR of 28.60% during the forecast period 2021-2027.
It is a sophisticated genome-editing technique that allows scientists to easily change DNA sequences and gene function. It has a wide range of possible applications, including genetic defects rectification, disease treatment and prevention, and agricultural growth and resilience augmentation. Despite its promise, though, the technology raises ethical difficulties. The advancement of genome engineering and its prospective applications has had a significant impact on the healthcare and life science industries' future. Nevertheless, the business is spending a massive amount of money on R&D activities of CRISPR gene editing products and gene therapies.
Insight by Product Type
Based on product type, the global CRISPR gene editing market is bifurcated into CRISPR products and CRISPR services. The CRISPR products are further divided into kits & enzymes, libraries, design tools, antibodies, and others. The kits and enzymes are sub-divided into vector-based Cas9 and DNA-free Cas9. The CRISPR services are further divided into gRNA design and vector construction, cell line and engineering, screening services, and others. The kits and enzymes hold a significant share in the market. Because of its high orthogonality, versatility, and efficiency, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system was a game-changer in genome editing technology. The CRISPR services are anticipated to have a high ACGR during the forecast period
Insight by Application
Based on application, the global CRISPR gene editing market is segregated into agriculture, biomedical, industrial, and others. The biomedical is further divided into gene therapy, drug discovery, and diagnostics. The biomedical dominates the CRISPR gene editing market owing to the rising number of gene therapy clinical trials, increased adoption of CRISPR editing techniques in various fields of biomedical research, and use of nano-carriers and advancement of new delivery methods will significantly enhance the effectiveness and uniqueness of the technology.
Insight by End-User
Based on end-user, the global CRISPR gene editing market is classified into academic institutes and research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical and biopharmaceutical companies. CRISPR technology is being used to boost the productivity of CHO cell lines in a big way. Large molecule therapeutics are frequently produced using these cell lines. As a result of the CRISPR tool's deployment, the biopharmaceutical market is seeing developments, which is fueling the market for the CRISPR gene editing market.
CRISPR Gene Editing Market Report Coverage
Base Year Considered
Market Size in 2021
Revenue Forecast in 2027
Segments Covered in the Report
By Product Type , By Application, and By End-User
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report
North America, Europe, Asia-Pacific, Middle East, and Rest of the World
The increased funding from the private and government sectors along with a surge in technological development are the trends prevalent in the CRISPR gene editing market.
Factors attributing to the growth of the CRISPR gene editing market include rising demand from the food industry to offer superior products having enhanced quality and enrich in nutrients and rising demand from the pharmaceutical industry to offer treatment of various diseases. Also, to enhance specificity and cost-effectiveness, as well as reduce turnaround time and human errors, research organizations, pharmaceutical and biotechnology firms, and institutes are striving for more efficient genome editing technologies. Moreover, the growing geriatric population, as well as the increasing number of cancer cases and genetic abnormalities around the world, are predicted to drive up demand for CRISPR gene editing. In recent times, the number of clinical trials for numerous genetic and chronic disorders has increased. This will contribute to the future expansion of the CRISPR gene editing business.
The off-target effects and delivery are expected to stymie the expansion of the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market during the forecast period. Also, the ethical concerns, pending patent issues & results of clinical trials, lack of healthcare budgeting in emerging economies, misuse of CRISPR technology, and consequences related to human genome editing will pose a challenge in the growth of the CRISPR gene editing market.
The development of the worldwide CRISPR gene editing market has been pushed in recent years by the emergence of new cell and gene therapy production centers, partnerships among biotechnology firms, and significant investments, thus creating opportunities for the market. Furthermore, the advancement of genome editing technologies has allowed researchers to investigate a wide range of applications in domains such as industrial, biotechnology, and agricultural research. These sophisticated approaches are simple, super-efficient, and cost-effective, and they allow for multiplexing and high throughput.
North America contributes the largest share in the CRISPR gene editing market owing to significant investment by pharmaceutical and biotechnology companies. Also, the increased investment in healthcare infrastructure, rising per capita income, availability of new and developed research laboratories and institutions, and accessibility of approved therapies will accelerate the growth in the region.
The significant increase in the adoption of precision medicine globally will lead to investment by industry players to develop novel CRISPR gene editing. Furthermore, the increasing strategic alliances, partnerships, and collaboration will lead to a strong foothold by the industry players in the market.
Merck's expertise in genome editing has resulted in the industry's most comprehensive portfolio of CRISPR and other advanced genomics technologies, which has an impact on every step of the process, from basic research to therapeutic delivery. Gene knockout, targeted integration and mutagenesis, and genetic screening libraries are among the technologies and services offered by the company to help research immune therapeutics, cancer, and infectious illness, among other sectors. Merck's experts are working on new technologies that will increase these uses and speed up health-related research.
CRISPR Therapeutics is a leading gene-editing firm that uses its unique CRISPR/Cas9 gene-editing platform to generate transformational gene-based treatments for critical diseases. CRISPR/Cas9 is a breakthrough technique for making precise, targeted alterations to genomic DNA. The Company's multidisciplinary team of world-class researchers and drug developers is working to turn this technology into revolutionary human therapeutics for a variety of critical disorders. CRISPR Therapeutics has also formed strategic partnerships with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics for diseases where there is a high unmet need.
In October 2021, Merck, a prominent scientific and technology corporation, announced that Cellecta, Inc., a functional genomics products and services provider based in Mountain View, California, has inked an agreement licensing its proprietary CRISPR-Cas9 technology. Merck is paving the way for researchers and scientists to uncover and accelerate next-generation treatments for inherited blood disorders, cancers, and ophthalmological diseases, among others by licensing its revolutionary technologies.
In December 2021, Invitrogen TrueCut HiFi Cas9 Protein, a novel protein from Thermo Fisher Scientific, has been added to Thermo Fisher Scientific's increasing CRISPR gene editing solutions portfolio. CRISPR technology, also known as in vivo gene editing, has grown in popularity as a technique for modifying human DNA. In various cell types, including T cells and induced pluripotent stem cells, the Invitrogen TrueCut HiFi Cas9 Protein minimizes off-target effects as compared to wild-type Cas9 (iPSCs).
Some of the major players in the global CRISPR gene editing market include Merck KGaA, Thermo Fisher Scientific Inc., Applied StemCell, Abcam plc, CRISPR Therapeutics, Cellecta, Inc., GenScript, ToolGen, Inc., Takara Bio Inc., and OriGene Technologies, Inc.
To explore more about this report - Request a free sample copy
The CRISPR Gene Editing Market report offers comprehensive market segmentation analysis along with estimation for the forecast period 2021–2027.
Segments Covered in the Report
• By Product Type
- CRISPR Products
> Kits & Enzymes
> Design Tools
- CRISPR Services
> gRNA Design and Vector Construction
> Cell Line and Engineering
> Screening Services
• By Application
• By End User
- Academic Institutes and Research Centers
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Pharmaceutical and Biopharmaceutical Companies
Region Covered in the Report
• North America
- Rest of Europe
• Asia-Pacific (APAC)
- South Korea
- Rest of Asia-Pacific
• Rest of the World (RoW)
- Saudi Arabia
- South Africa
- Other Countries